Category Archives: Alzheimer’s Disease International (ADI)

Alzheimer’s Disease International (ADI)

The State of Dementia Research Globally: World Alzheimer Report 2018 (Alzheimer’s Disease International)

Posted on March 2, 2019 by Dementia and Elderly Care News

Summary The World Alzheimer Report 2018, entitled “The state of the art of dementia research: New frontiers”, reviews developments in dementia research, without glossing-over the absence of significant disease-modifying pharmacological treatment breakthroughs for around 20 years. This report examines wide-ranging … Continue reading →

Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest | Tagged ADI’s World Alzheimer Reports, Alireza Atri: Director of Banner Sun Health Research Institute, Alzheimer's Research, Alzheimer’s Disease International (ADI), Alzheimer’s Disease Research Unit: McGill Centre for Studies in Ageing (Canada), Alzheimer’s Prevention Initiative: Banner Health (USA), Alzheimer’s Prevention Initiative: Banner Sun Health Research Institute, Banner Sun Health Research Institute, Burden of Alzheimer’s Disease, Burden of Dementia (Statistics), Centre for Dementia Prevention: University of Edinburgh, Dementia as Cause of Death, Dementia Awareness, Dementia Awareness Raising, Dementia Collaborative Research Centre: University of New South Wales, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Prevention, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Dr Christopher Chen: Director of Memory Ageing and Cognition Centre at National University Health System: Singapore, Dr Doug Brown: Chief Executive Officer of British Society for Immunology, Dr Doug Brown: Former Chief Policy and Research Officer at Alzheimer’s Society, Dr Jennifer Bute: Dementia Alliance International (DAI), Dr Kenji Toba: President of National Centre for Geriatrics and Gerontology (Obu), Dr Maria Carrillo: Chief Science Officer at Alzheimer’s Association US, Dr Miia Kivipelto: Karolinska Institute, Dr Miia Kivipelto: Karolinska University Hospital (Stockholm), Dr Rachelle Doody: Global Head of Neurodegeneration at Roche, Dr Serge Gauthier: Director of Alzheimer’s Disease Research Unit at McGill Centre for Studies in Ageing in Canada, Drug Trials Failure Rate, Epidemiology, Epidemiology and Statistics, Francesca Colombo: Organisation for Economic Co-operation and Development (OECD), Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Glenn Rees: Chairman of Alzheimer’s Disease International, Glenn Rees: Former CEO of Alzheimer’s Australia, Global Burden of Dementia, Global Dementia Discovery Fund (2015), Identification and Intervention for Dementia in Elderly Africans (IDEA Group), Jeff Cummings: Director of Cleveland Clinic at Lou Ruvo Centre for Brain Health, Kate Bingham: SV Health Managers, King’s College London, Market Failure (Dementia Research and Drug Development), Martin Knapp: London School of Economics, Memory Ageing and Cognition Centre at National University Health System: Singapore, Memory Ageing and Cognition Centre: National University Health System (Singapore), National Centre for Geriatrics and Gerontology (Japan), Optima (University of Oxford’s Dementia Research Project), OPTIMA Cohort (Oxford Project to Investigate Memory and Ageing), Oxford Project to Investigate Memory and Ageing (OPTIMA Study), Paola Barbarino: Alzheimer’s Disease International, Prevention, Prevention Agenda, Prevention of Future Dementia Cases by Increasing Knowledge of Risk and Protective Factors, Professor Adesola Ogunniyi: University College Hospital (Ibadan), Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Craig Ritchie: Chair of Psychiatry of Ageing at University of Edinburgh, Professor Craig Ritchie: Director at Centre for Dementia Prevention, Professor Gordon Wilcock: Co-founder of Alzheimer’s Society UK, Professor Gordon Wilcock: Emeritus Professor of Geratology at University of Oxford, Professor Henry Brodaty: Director of Dementia Collaborative Research Centre at University of New South Wales, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), Professor Martin Prince: Assistant Principal for Global Health at King’s College London, Research Networks, Ricardo Allegri: Head of Cognitive Neurology Neuropsychology and Neuropsychiatry at Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Risk and Protective Factors, State of the Art of Dementia Research: New Frontiers (World Alzheimer Report 2018), Supporting People Affected by Dementia, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College Hospital (Ibadan Nigeria), World Alzheimer Report, World Alzheimer Report 2018: State of the Art of Dementia Research, World Alzheimer Report: 2018, World Alzheimer’s Day 2018 | Leave a comment

Dementia Medication De-Listed in France: Untruth, Half-Truth or Paternalistic News Blackout? (BBC News / Prescrire / ADI / Inside Health / JAMA Network Open)

Posted on October 18, 2018 by Dementia and Elderly Care News

Summary Early evening headlines yesterday, on BBC Radio 4 news, announced the “shocking” news that drugs for Alzheimer’s Disease / dementia had been de-listed in France. This story has not been followed-up, and appears to have been dropped quietly; although … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Universal Interest | Tagged Adverse Drug Reactions, Adverse Effects, Alpha-7 Nicotinic Acetylcholine Receptor (α7nAChR), Alzheimer's Disease: Monotherapy Versus Combination Therapy, Alzheimer's Research and Therapy, Alzheimer’s Disease International (ADI), Alzheimer’s Disease International (ADI) Campaigns, American Family Physician, Anti-Dementia Medication, Augusta University, BBC Radio 4, BBC Radio 4's Inside Health Programme, BBC Radio 4’s PM Programme, Big Pharma, Cholinergic-Nicotinic System, Choosing Wisely, Clinic for Medicine of the Elderly (Hannover), Conflict of Interests, Conflicts of Interest, Department of Behavioral Neuroscience and Drug Development: Polish Academy of Sciences, Department of Psychiatry and Behavioral Health: Marshfield Clinic Health System, Department of Psychiatry and Behavioral Sciences: George Washington University School of Medicine and Health Sciences, Department of Psychiatry and Health Behavior: Augusta University, Deprescribing, Donepezil, Donepezil-Memantine Combination, Donepezil-Memantine: Monotherapy Versus Combination Therapy, Drug Efficacy, Drug Side-Effects, Drugs Alleged to Raise False Hopes (Speculative Construct), Family Medicine Residency Program: Southern Illinois University School of Medicine, Family Physicians Inquiries Network (FPIN), Formindep: Non-Profit Organisation Promoting Independence From Industry Influence, France, France's National Authority for Health (HAS), French Ministry of Health and Solidarity, French National Dementia Guidelines, Galantamine, Galantamine-Memantine Combination Versus Donepezil-Memantine Combination, Galantamine-Memantine Drug Combination, George Washington University School of Medicine and Health Sciences, Germany, Glutamatergic Receptor Systems, Glutamatergic System, Harms of Too Much Medicine, Institute of Pharmacology: Polish Academy of Sciences, JAMA Network Open, Janssen Research and Development, Journal of Geriatric Care and Research (JGCR), Keck School of Medicine: University of Southern California, KYNA/3-HK, KYNA/KYN, KYNA/QUIN, Kynurenic Acid, Kynurenine Pathway, Marshfield Clinic Health System (USA), Medical College of Georgia: Augusta University, Memantine, Ministry of Health and Solidarity (France), Mismatch Negativity (MMN), Mount Sinai Medical Center (New York), National Institutes of Health (NIH), National Institutes of Health (US), Neurotransmitter Systems in Alzheimer’s Disease, NMDA (N-Methyl-D-Aspartate), Over-Treatment, Oxidative Stress, Paola Barbarino: Alzheimer’s Disease International, Poland, Polish Academy of Sciences, Prescrire in English [the Prescriber] / Rev. Prescrire, Reducing Waste in Dementia Care, Reducing Waste in the NHS, Rivastigmine, Serge Gauthier: ADI’s Medical and Scientific Advisory Panel (MSAP), Society of Biological Psychiatry (SOBP), Southern Illinois University, Southern Illinois University School of Medicine, Synaptec Inc (Florida), Too Much Medicine, United States, University of Alabama at Birmingham, University of Southern California, USA | Leave a comment

More on the Disproportionately High Impact of Dementia Upon Women (GADAA)

Posted on September 25, 2017 by Dementia and Elderly Care News

Summary Women comprise roughly 65% of people with dementia in the UK. They are disproportionately affected by the condition in terms of having to assume caring responsibilities. The main section headings in this report comprise: Chapter 1: Key Challenges. An … Continue reading →

Healthcare Pathways For People Living With Dementia: World Alzheimer Report 2016 (Alzheimer’s Disease International)

Posted on October 6, 2016 by Dementia and Elderly Care News

Summary The World Alzheimer Report 2016, entitled “Improving healthcare for people living with dementia” reviews evidence on aspects of healthcare for people with dementia and suggests how improvements and efficiency savings can be made. The authors are against over-specialization of … Continue reading →

Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Commissioning, Community Care, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Quick Insights, Standards, Statistics, Systematic Reviews, UK, Universal Interest | Tagged 10/66 Dementia Research Group, Access to Palliative Care, ADI’s World Alzheimer Reports, Advance Care Planning (ACP), Ageing Population, Ageing Society, Alzheimer’s Disease International (ADI), Alzheimer’s Disease International’s 10/66 Dementia Research Group, Benefits of Case Management, Better Policies for People with Dementia, Canada, Canadian Centre for Family Medicine Family Health Team (CCFM-FHT) Ontario Memory Clinic, Canadian Comfort Care Booklet, Canadian Comfort Care Principles, Canadian Mild Dementia Knowledge Transfer Toolkit, Care Coordination / Case Management Approaches For People With Dementia Living at Home, Care Coordination and Navigation, Case Management for Dementia, Challenges of Living with Dementia, China, Clinical Practice Guidelines and Care Pathways for People with Dementia Living in the Community (Queensland University of Technology), Community Care, Community Care Services, Community-Based Care, Community-Based Care for People With Dementia, Cost Implications of Dementia Healthcare Pathways, Counter-Factual Service Modelling, Dedicated Care Coordination, Dementia Care in Acute General Hospitals, Dementia Care Pathways, Dementia Healthcare Pathways, Dementia Post-Diagnostic Care and Support, Dementia Research Priorities For Healthcare Sector (WHO Research Prioritization Exercise), Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia: Prevalence and Detection, Early Detection of Alzheimer’s Disease, European Association for Palliative Care White Paper, Global Action Against Dementia, Global Burden of Dementia, Global Context, Global Costs of Dementia, Global Dementia Crisis, Global Dementia Crisis: Adaptations to Services, Global Dementia Crisis: Re-Balancing of Funding For Services, Global Dementia Crisis: Re-Balancing of Services, Global Health, Global Observatory for Ageing and Dementia Care, Global Observatory for Ageing and Dementia Care: King’s College London, Global Outlook, Health Service and Population Research Department: King’s College London, Improving Healthcare For People Living With Dementia: World Alzheimer Report 2016, Improving Outcomes for People Living With Dementia, Indonesia, Integrated and Community-Based Care, Integration of Primary Secondary and Community Care, King’s College London, Living with Dementia, London School of Economics and Political Science (LSE), LSE's Personal Social Services Research Unit (PSSRU), Managing Comorbidity and Complexity, Mexico, Palliative Care, Personal Social Services Research Unit (PSSRU), Personal Social Services Research Unit (PSSRU): London School of Economics and Political Science, Primary Care, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), PSSRU at London School of Economics and Political Science, Queensland University of Technology Clinical Practice Guidelines and Care Pathways for People with Dementia Living in the Community, South Africa, South Korea, Switzerland, Systematic Reviews and Meta-Analyses, Task-Sharing, Task-Shifting, Typical Duration of Care Inputs Across the Care Pathway, Typical Intensity / Frequency of Care Inputs Across the Care Pathway, World Alzheimer Report 2016, World Health Organization Mental Health Gap Action Programme (mhGAP) Evidence Based Guidelines | Leave a comment

World Alzheimer’s Day and World Alzheimer’s Month 2016 (Alzheimer’s Disease International)

Posted on September 18, 2016 by Dementia and Elderly Care News

Summary Information is available from Alzheimer’s Disease International (ADI) concerning World Alzheimer’s Month (September); and World Alzheimer’s Day 2016, on September 21st 2016. The theme for this year’s World Alzheimer’s Month campaign is “Remember Me”. World Alzheimer’s Month is a … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Disease International (ADI), Charitable Bodies, In the News, International, Mental Health, Models of Dementia Care, Patient Information, Person-Centred Care, Personalisation, Quick Insights, Scotland, UK, Universal Interest | Tagged 20000 Reasons Campaign (Alzheimer's Society: Northern Ireland), 45000 Reasons Campaign (Alzheimer's Society: Wales), Albania, Argentina, Armenia, Aruba, Australia, Austria, Awareness, Awareness Campaigns, Awareness Raising, Bahrain, Bangladesh, Barbados, Belgium, Bermuda, Bolivia, Brazil, Brunei, Bulgaria, Canada, Carey Mulligan, Carey Mulligan: UK Global Dementia Friends Ambassador, Cayman Islands, Chile, China, Chinese Taipei, Colombia, Costa Rica, Croatia, Cuba, Curaçao, Cyprus, Czech Republic, Dementia Awareness Campaigns, Dementia Awareness Raising, Dementia Friends, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Ethiopia, Finland, France, Germany, Ghana, Gibraltar, Global Outlook, Greece, Guatemala, Honduras, Hong Kong SAR, Hungary, Iceland, India, Indonesia, Iran, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Lebanon, Luxembourg, Macau (SAR China), Macau SAR, Macedonia, Madagascar, Malaysia, Malta, Mauritius, Mexico, Monaco, Morocco, Namibia, Nepal, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Pakistan, Peru, Philippines, Poland, Portugal, PR China, Puerto Rico, Romania, Russia, Saudi Arabia, Scotland, Serbia, Singapore, Sint Maarten, Slovak Republic, Slovenia, South Africa, South Korea, Spain, Sri Lanka, St Kitts and Nevis, Suriname, Sweden, Switzerland, Syria, TADA Chinese Taipei, Thailand, Trinidad and Tobago, Tunisia, Turkey, Ukraine, Uruguay, USA, Venezuela, World Alzheimer's Month 2016 (Remember Me), World Alzheimer’s Day 2016, World Alzheimer’s Month 2016, Zimbabwe | Leave a comment

Faintest Hints of Promise From a Recent Dementia Drug Trial? (BBC News / Alzheimer’s Association International Conference)

Posted on July 28, 2016 by Dementia and Elderly Care News

Summary Data from a recent trial involving 891 patients, presented at the Alzheimer’s Association International Conference in Toronto this week, indicates that an experimental new drug (LMTX) appears to slow the death of brain cells and preserve mental function in … Continue reading →

Posted in Alzheimer’s Disease International (ADI), BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Abnormal Proteins (Tau), Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging (Douglas Mental Health University Institute), Alzheimer's Disease Research Unit: McGill University (Canada), Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, BBC Health News, Degenerative Tauopathy, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Douglas Mental Health University Institute: McGill University Research Centre for Studies in Aging, Dr Serge Gauthier: Director of Alzheimer's Disease Research Unit at McGill University in Canada, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Global Dementia Research, Leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), Leucomethylthioninium Salts (LMTX), LMTM Monotherapy, LMTX, Ltd., Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Tau, Tau Aggregation, Tau Aggregation Inhibitor Therapy, Tau Aggregation Inhibitors, Tau Pathology, Tau Tangles, Tau-Targeting Drugs, Tauopathy, TauRX, TauRx Therapeutics, Treatment and Prevention of Dementia | Leave a comment

Significant Changes at the World Dementia Council? (WDC)

Posted on February 28, 2016 by Dementia and Elderly Care News

Summary There has been reform within the World Dementia Council (WDC). The changes are intended to make this body “more representative” in global terms (if such were possible) and fully independent. The Council now includes a wider range of international … Continue reading →

Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, Charitable Bodies, Commissioning, Department of Health, Diagnosis, For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, UK, Universal Interest, World Health Organization (WHO) | Tagged Abuse of Vulnerable Adults, Academia-Industry Partnerships, Academic Research, Alternatives to Antipsychotic Drugs, Alzheimer's Association, Alzheimer’s Disease: Risk Factors, Alzheimer’s Research UK (ARUK), Argentina, ARUK: Alzheimer’s Research UK, Assistive Technology, Associate Members (WDC), Awareness, Awareness Raising, Behavioural Risk Factors, Big Data, Big Data Partnership, Big Pharma, Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Biotechnology, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Challenge, Dementia Consortium, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Friends, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Dementia Risk Factors, Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dennis Gillings: Former World Dementia Envoy, Department of Health Dementia Challenge, Department of Health’s Integrated Development Initiative, Digital Technology, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Yves Joanette: Scientific Director of Canadian Institute of Health Research (Institute of Aging), Emerging Technology, Enabling Technology, Future Long-Term Care Costs, GAAD: Global Action Against Dementia, Global Action Against Dementia, Global Action Against Dementia (GAAD), Global Outlook, Global Social Investment for Dementia, Government Research Funding, Hilary Doxford: World Dementia Council Member, Indonesia, Information Technology, Innovative Technology, International Collaborations, International Dementia Research Inventories, International Programmes, Interventions for Social Isolation and Loneliness in Men, Investment in Technology, Join Dementia Research, Leveraging Big Data, Lifestyle Risk Factors, Loneliness and Social Isolation, Modifiable Risk Factors, National Institute of Ageing (NIA), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, Nigeria, Open Data and Big Data, Organisation for Economic Co-operation and Development (OECD), Partnership and Collaboration, Partnership Working, Philanthropic Funding, Pipeline Databases, Prevention, Prevention of Dementia, Prime Minister’s Challenge On Dementia 2020, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Raj Long: Vice Chair of World Dementia Council, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Stigma, Regulatory Agencies, Regulatory Experts, Research and Development, Research and Innovation, Research Commitment, Research Funding, Resource and Incentives, Restraint and Restrictions, Restraint in Health and Adult Social Care, Risk Factors, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Social Isolation, Stigma, Taiwan, Treatment and Prevention of Dementia, US National Institute on Aging, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO), Yves Joanette: Chair of World Dementia Council | Leave a comment

Category Archives: Alzheimer’s Disease International (ADI)

Dementia Medication De-Listed in France: Untruth, Half-Truth or Paternalistic News Blackout? (BBC News / Prescrire / ADI / Inside Health / JAMA Network Open)

World Alzheimer’s Day and World Alzheimer’s Month 2016 (Alzheimer’s Disease International)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites